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Abbreviations               
BAT – basophil activation test 
Can f – Canis familiaris 
CD – circular dichroism 
CDE – cat dander extract 
ELISA – enzyme-linked immunosorbent assay 
Fel d – Felis domesticus 
 
Abstract  
We investigated the prevalence of sensitization to the cat lipocalin Fel d 7 among 140 cat-
sensitized Swedish patients and elucidated its allergenicity and cross-reactivity with the dog 
lipocalin Can f 1. Sixty-five of 140 patients had IgE to rFel d 7 whereof 60 also had IgE to 
rCan f 1. A moderate correlation between IgE levels to rFel d 7 and rCan f 1 was found. rFel d 
7 activated basophils in vitro and inhibited IgE-binding to rCan f 1 in 4/13 patients, whereas 
rCan f 1 inhibited IgE-binding to rFel d 7 in 7/13 patients. Fel d 7 and Can f 1 showed high 
similarities in protein structure and epitopes in common were found by using cross-reactive 
antisera. Fel d 7 is a common allergen in a Swedish cat-sensitized population that cross-reacts 
with Can f 1, and may contribute to symptoms in cat- but also in dog-allergic patients. 
 
Introduction 
Allergy to pets like cat (Felis domesticus) and dog (Canis familiaris) is the second most 
common indoor allergy in the western world affecting both children and adults (1, 2). Many 
patients are co-sensitized to cat and dog (3, 4), suggesting allergenic cross-reactivity. 
Lipocalins constitute the largest mammalian allergen family (5, 6). They are found in body 
fluids and secretions (7, 8), and despite the highly conserved structure, the sequence identity 
between lipocalins is generally low (9). The major dog allergen Can f 1 together with Can f 2, 
Can f 4 and Can f 6 belong to the lipocalin family (10, 11). With respect to cat, the minor cat 
allergen Fel d 4 and the newly identified Fel d 7 are lipocalins (12).  The degree of allergenic 
cross-reactivity between lipocalins varies (9, 13) and it has been reported that the dog Can f 6 
cross-reacts with the cat Fel d 4, as well as the horse Equ c 1 (14, 15). Cross-reactivity 
between Can f 2 and Fel d 4 has also been reported (11). 
Fel d 7 and Can f 1 have sequence identity close to 60%, indicating potential cross-reactivity 
(12, 16). Sensitization to Fel d 7 has reported to be common (38%) among cat allergic patients 
in Australia (12). More information regarding the prevalence of IgE recognition of Fel d 7 and 
its cross-reactivity and allergenicity is needed. We have investigated the prevalence of 
sensitization to Fel d 7 in a Swedish cat-sensitized population and elucidated the allergenicity 
of Fel d 7 and its role in cross-reactivity with Can f 1 on an epitope level.  
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Methods 
For details, see the supporting information 
Study population 
Sera from 140 Swedish patients with an IgE antibody level >2 kUA/l (median 14.0, range 2.2-
190 kUA/l) to cat dander extract (CDE) and 45 cat IgE negative sera (<0.1 kUA/l) were 
collected at the Department of Clinical Immunology at Karolinska University Hospital, 
Stockholm. In addition, four patients with doctor’s diagnosed allergy to cat and IgE-positive 
to Fel d 7 were included for basophil activation test (BAT). The study was approved by the 
local ethics committee. 
Allergen preparations and characterization 
Recombinant (r) Fel d 7 and Can f 1 were produced and characterized as previously described 
(11, 12). IgE levels to rFel d 7 and rCan f 1 were determined by ELISA (11). Spearman’s 
correlation test was used for comparing rFel d 7- and rCan f 1-specific IgE levels, where 
p<0.05 was considered significant.  
Basophil activation test and IgE cross-reactivity between Fel d 7 and Can f 1 
Allergenicity was analyzed by BAT (17). The potential cross-reactivity between IgE to Fel d 
7 and Can f 1 was investigated by inhibition ELISA. 
Identification and molecular modeling of Fel d 7 cross-reactive epitopes 
Six overlapping peptides spanning the Can f 1 sequence (Table S1) were synthesized as 
described (18). Peptide-specific IgG antibodies were obtained by immunizing rabbits with the 
corresponding Can f 1-peptides. Can f 1-peptide antisera were used to evaluate cross-reactive 
binding sites between Can f 1 and Fel d 7.  
A molecular model comparing Fel d 7 and Can f 1 was created based on the human tear 
lipocalin/von Ebners gland protein structure (PDB entry 3EYC_A) using SWISS-MODEL 
(19) and PyMOL (www.pymol.org).  
 
Results 
IgE-reactivity and allergenicity of Fel d 7 and Can f 1 in Swedish cat dander-sensitized 
patients 
Sixty-five of 140 (46.4%) Swedish cat-sensitized patients were rFel d 7-positive (median 
2.76, range 0.16-37 kUA/l, Table S2) and almost all of those (92.3%) were rCan f 1-positive 
(median 8.11, range 0.17–33 kUA/l). A moderate correlation between IgE levels to rFel d 7 
and rCan f 1 was found (rho=0.62, p<0.0001, Figure 1A). IgE levels to dog dander extract 
among the rFel d 7-positive patients (median 14, range 0.12-95 kUA/l) were similar compared 
to CDE levels (median 14, range 2.2-190 kUA/l). The allergenicity of rFel d 7 in relation to 
rCan f 1 was investigated in a BAT using blood from Fel d 7-sensitized cat-allergic patients 
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whereof two were also co-sensitized to Can f 1 (Table S3). rFel d 7 induced basophil 
degranulation in all patients, while rCan f 1 induced a similar response in the two Can f 1 co-
sensitized patients (Figure 1B). No activation was seen upon stimulation with controls (data 
not shown). 
IgE cross-reactivity between Fel d 7 and Can f 1 
IgE cross-reactivity was evaluated in sera from 13 patients IgE-positive to rFel d 7 and rCan f 
1, with five representative patients shown in Figure 1C and the eight remaining patients 
shown in Figure S1. At the highest concentration (1μg/ml), rFel d 7 inhibited at least 70% of 
the IgE-binding to rCan f 1 in four patients, whereas 1μg/ml of rCan f 1 inhibited more than 
90% of the IgE-binding to rFel d 7 in seven patients. Notably, rFel d 7 and rCan f 1 were 
equally low in heterologous inhibitions for two patients (# 5 and 6). Homologous inhibition 
reached at least 65% in four of five patients (Figure 1C). No inhibition of IgE-binding to Can 
f 1 was observed in Fel d 7 negative sera (data not shown). 
 
Can f 1 peptide antisera identify cross-reactive epitopes on Fel d 7 and Can f 1 
The primary structure of Fel d 7 shows high sequence identity (63%) with Can f 1 (Figure 
S2A) which is manifested by similar secondary and tertiary structures, as observed by CD 
spectra (Figure S2B). In the far-UV CD spectra there is a difference in molar elipiticity 
between these two allergens. The maximum at 195nm for rCan f 1 shows higher elipiticity 
than in rFel d 7. Furthermore, the CD spectrum of rCan f 1 has a clearly visible minimum at 
208nm, also representing α-helix content. Using the CONTINILL algorithm with SP37 base 
to calculate the percentage of secondary structures results in a total difference of 14.2% in 
sum of α-helix, β-sheets and β-turn structures between Fel d 7 and Can f 1 (Table S4). These 
differences can be also noticed in the near-UV CD spectra where the dissimilar molar 
elipticity probably is due to slight differences in local 3D environment of the aromatic 
chromophores.  
When investigating the locations of shared epitopes between Fel d 7 and Can f 1 using Can f 
1-peptide antisera, we found that all five antisera bound rFel d 7 and rCan f 1, while none of 
them bound the unrelated allergen Fel d 1 (Figure S3). Two of the rabbit antisera, covering 
the N- and C- terminal parts of Can f 1 (Peptide 1 and Peptide 6 in Table S1), displayed the 
strongest binding to rFel d 7. A 3D model comparing Fel d 7 and Can f 1 was created based 
on sequence homology to human tear lipocalin/von Ebners gland protein (Figure 2A and B) 
showing surface exposed cross-reactive epitopes (Figure 2C). 
 
Discussion 
This study shows that Fel d 7 is an important allergen in a Swedish cat-sensitized population 
as nearly half (46.4%) of the included patients had IgE-reactivity to Fel d 7, which was even 
higher than the prevalence reported among Australian cat-allergic patients (7). We noted that 
the majority of the rFel d 7 positive patients had correlating rCan f 1 IgE levels, indicating 
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IgE cross-reactivity between these lipocalins. However, when investigating the allergenicity 
by BAT, rCan f 1 only stimulated degranulation of basophils from the two patients that were 
co-sensitized to Can f 1. 
 
A previous report showed IgE cross-reactivity between Fel d 7 and dog dander extract in one 
out of two patients tested (12), but whether this inhibition could be assigned to Can f 1 was 
not explored. Overall we observed that the degree of cross-reactivity varied between the 
patients and did not always correlate with IgE levels to rFel d 7 and rCan f 1, which probably 
depended on differences in affinity to the respective allergens. Based on the inhibition results, 
half of the patients seem to be primarily sensitized to Can f 1. However, when also 
considering BAT, we identified some patients that were exclusively sensitized to Fel d 7. No 
inhibition of rCan f 1 by rFel d 7 was observed in patients IgE-negative to rFel d 7. These 
findings indicate that Fel d 7 and Can f 1 have epitopes in common but also have IgE-binding 
structures specific for each allergen. 
 
When exploring the location of cross-reactive structures on the allergens, we noted that rabbit 
antisera against peptides covering the N- and the C- terminal part of Can f 1 had a stronger 
IgG-binding to rFel d 7 compared to the other antisera. The free C- and N-terminals are 
regions where longer linear epitopes are exposed. The lower degree of binding of the antisera 
covering the middle part of the protein sequence could be due to the fact that this part harbors 
conformational epitopes and the antisera were produced against linear peptides. A 3D model 
was created to visualize where the potential cross-reactive sequences are located. The model 
revealed that the identical sequences of Fel d 7 and Can f 1 are exposed on the surface of the 
molecule, including the N- and C- termini, in line with our results from Can f 1 peptide 
antisera. 
 
In conclusion, we show that Fel d 7 is an important allergen in a Swedish cat-sensitized 
population that has a similar structure and shares epitopes with the major dog allergen Can f 
1. Our findings widen the understanding of allergenic cross-reactivity between cat and dog, 
where Fel d 7 may contribute to symptoms not only in cat- but also in dog-allergic patients by 
IgE cross-reactivity with Can f 1. Thus, including Fel d 7 in panels for pet allergy diagnosis 
has the potential of improving cat allergy diagnosis.  
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Figure legends 
Figure 1. IgE reactivity and allergenicity of rFel d 7 and rCan f 1 and their IgE cross-
reactivity 
(A) Comparison of Fel d 7- and Can f 1-specific IgE levels (kUA/l) in sera from Fel d 7-
positive subjects (n=65), using Spearman’s correlation test; (B) Allergenicity of rFel d 7 and 
rCan f 1 as determined by basophil activation in blood from four cat-allergic patients (#I-IV, 
Table S3) and one non-atopic control. Degranulation is presented as proportion (%) of CD63-
positive out of CD203c-positive cells by flow cytometry (y-axes) in response to different 
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allergen concentrations (x-axes); (C) Cross-inhibition and homologous inhibition of rFel d 7 
and rCan f 1 shown in five patients (2, 4, 6, 8, 14, Table S2). Percentages of inhibition (y-
axes) are plotted against different concentrations of inhibitor allergens (x-axes). IgE-binding 
to rCan f 1 in sera pre-incubated with rFel d 7–cross-inhibition (grey dots); IgE-binding to 
rFel d 7 in sera pre-incubated with rCan f 1–cross-inhibition (black squares); IgE-binding to 
rFel d 7 in sera pre-incubated with rFel d 7–homologous inhibition (dark gray triangles); IgE-
binding to rCan f 1 in sera pre-incubated with rCan f 1–homologous inhibition (open 
triangles).  
 
Figure 2. Fel d 7 and Can f 1 cross-reactive epitopes  
(A) Ribbon representation and (B) surface representation of a 3D model comparing Fel d 7 
and Can f 1, based on the human tear lipocalin protein structure (PDB entry 3EYC_A). Pink 
color corresponds to identical sequences present in all three proteins. Blue color corresponds 
to identical sequences present only in rFel d 7 and rCan f 1. Grey color corresponds to 
sequences which are not identical with Fel d 7 and/or Can f 1; (C) 3D ribbon (left) and 
surface representation (right) with highlighted peptides at the N- (Green: Peptide 1 in Table 
S1) and C-terminal (Red: Peptide 6 in Table S1).  
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